Loading stock data…
Senseonics Holdings (SENS)
$4.86-0.01 (-0.21%)
Market ClosedLast close Jul 24
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Senseonics Holdings, Inc. in the Healthcare sector is trading at $4.86 with a market capitalization of $378M. Wall Street consensus targets $13.40 (5 analysts), implying a +175.7% move over the next 12 months. The stock is currently near its 52-week low of $4.79, remaining 26.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +175.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 17) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.71M↓ | $14.26M↑ | $8.10M↑ | $6.65M↑ | $6.26M |
| Gross Profit | $6.94M↓ | $7.67M↑ | $3.47M↑ | $3.12M↑ | $1.50M |
| Operating Income | -$31.85M↓ | -$20.93M↓ | -$19.60M↓ | -$14.32M↓ | -$13.49M |
| Net Income | -$32.33M↓ | -$20.82M↓ | -$19.53M↓ | -$14.50M↓ | -$14.26M |
Peer Comparison
JNJUNHPFE
Fundamentals
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$377.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-253.93%
Volume
Today's trading volume
443,099
Recent News
DXCM Grew. The Stock Did Not. Someone Is Wrong
The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.
Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM
By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.
Senseonics Holdings (SENS) Stock Fair Value Moves Lower After Analysts Cut Growth Assumptions
Analysts have reset their average price target for Senseonics Holdings to about US$13.80, down from around US$18.92, reflecting a roughly 27% cut in the equity value embedded in their models. Recent commentary focuses on how this new target lines up with the current share price, with some firms stressing potential upside if the company executes well and others emphasizing the risks that led them to trim expectations. As you read on, you will see how these shifting targets shape the evolving...
Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system and the integration of its U.S. commercial organization. President and CEO Tim Goodnow said